{
    "clinical_study": {
        "@rank": "102694", 
        "arm_group": [
            {
                "arm_group_label": "TravA/Brinz", 
                "arm_group_type": "Experimental", 
                "description": "Dose Level A / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks"
            }, 
            {
                "arm_group_label": "TravB/Brinz", 
                "arm_group_type": "Experimental", 
                "description": "Dose Level B / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks"
            }, 
            {
                "arm_group_label": "TravC/Brinz", 
                "arm_group_type": "Experimental", 
                "description": "Dose Level C / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks"
            }, 
            {
                "arm_group_label": "AZOPT", 
                "arm_group_type": "Active Comparator", 
                "description": "Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks"
            }, 
            {
                "arm_group_label": "TRAVATAN Z", 
                "arm_group_type": "Active Comparator", 
                "description": "Brinzolamide suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks"
            }, 
            {
                "arm_group_label": "TRAVATAN Z + AZOPT", 
                "arm_group_type": "Active Comparator", 
                "description": "Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate Travoprost/Brinzolamide fixed combination\n      (Trav/Brinz) administered twice daily as compared to each of its marketed components\n      (TRAVATAN Z\u00ae solution and AZOPT\u00ae suspension) and to the unfixed combination of TRAVATAN Z\u00ae\n      plus AZOPT\u00ae in lowering intraocular pressure (IOP)."
        }, 
        "brief_title": "6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is divided into two phases conducted in sequence. Phase I is the\n      Screening/Eligibility Phase, which includes a Screening Visit, followed by two Eligibility\n      Visits. Phase II is the randomized, double-masked, 6-week Treatment Phase which includes\n      on-therapy visits at Week 2 and Week 6."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with open-angle glaucoma (including open-angle glaucoma with\n             pseudoexfoliation or pigment dispersion) or ocular hypertension;\n\n          -  IOP within the protocol-specified range at both the Eligibility 1 and 2 Visits.  Mean\n             IOP must not be >36 mmHG at any time point;\n\n          -  Able to understand and sign an informed consent form;\n\n          -  Other protocol-specified inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Woman of childbearing potential who is currently pregnant, intends to become pregnant\n             during the study period, breastfeeding, or not using adequate birth control methods\n             to prevent pregnancy throughout the study;\n\n          -  Unable to discontinue all IOP-lowering ocular medication(s) per the appropriate\n             washout schedule prior to the E1 Visit;\n\n          -  Chronic, recurrent or severe inflammatory eye disease;\n\n          -  Ocular trauma within the past 6 months prior to the Screening Visit;\n\n          -  Ocular infection or ocular inflammation within the past 3 months prior to the\n             Screening Visit;\n\n          -  Clinically relevant or progressive retinal disease such as retinal degeneration,\n             diabetic retinopathy, or retinal detachment;\n\n          -  Best-corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to\n             approximately 0.60 logMAR, 20/80 Snellen, or 0.25 decimal);\n\n          -  Other ocular pathology (including severe dry eye) that may, in the opinion of the\n             Investigator, preclude the administration of a topical prostaglandin analogue or\n             topical carbonic anhydrase inhibitor;\n\n          -  Intraocular surgery within the past 6 months prior to the Screening Visit;\n\n          -  Ocular laser surgery within the past 3 months prior to the Screening Visit;\n\n          -  Any abnormality preventing reliable applanation tonometry;\n\n          -  Any other conditions including severe illness which would make the subject, in the\n             opinion of the Investigator, unsuitable for the study;\n\n          -  History of hepatic or renal disease that would preclude the safe administration of a\n             carbonic anhydrase inhibitor (CAI) in the opinion of the Investigator;\n\n          -  Hypersensitivity to prostaglandin analogues, topical or oral CAIs, sulfonamide\n             derivatives, or to any component of the study medications in the opinion of the\n             Investigator;\n\n          -  Recent (within 4 weeks of the Eligibility 1 Visit) use of high dose (> 1 g daily)\n             salicylate therapy;\n\n          -  Use of any additional topical or systemic ocular hypotensive medication during the\n             study;\n\n          -  Concurrent use of glucocorticoids administered by any route;\n\n          -  Less than 30 days stable dosing regimen before the Screening Visit of any medications\n             (excluding the IOP-lowering treatments) or substances administered by any route and\n             used on a chronic basis that may affect IOP (ie, \u03b2 adrenergic blocking agents);\n\n          -  Therapy with another investigational agent within 30 days prior to the Screening\n             Visit;\n\n          -  Other protocol-specified exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "288", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02140060", 
            "org_study_id": "C-14-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "TravA/Brinz", 
                "description": "Fixed combination", 
                "intervention_name": "Dose Level A / Brinzolamide 1% ophthalmic suspension", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TravB/Brinz", 
                "description": "Fixed combination", 
                "intervention_name": "Dose Level B / Brinzolamide 1% ophthalmic suspension", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TravC/Brinz", 
                "description": "Fixed combination", 
                "intervention_name": "Dose Level C / Brinzolamide 1% ophthalmic suspension", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "AZOPT", 
                    "TRAVATAN Z + AZOPT"
                ], 
                "intervention_name": "Brinzolamide 1% ophthalmic suspension AZOPT\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "AZOPT\u00ae"
            }, 
            {
                "arm_group_label": [
                    "TRAVATAN Z", 
                    "TRAVATAN Z + AZOPT"
                ], 
                "intervention_name": "Travoprost 0.004% ophthalmic solution TRAVATAN Z\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "TRAVATAN Z\u00ae"
            }, 
            {
                "arm_group_label": [
                    "TravA/Brinz", 
                    "TravB/Brinz", 
                    "TravC/Brinz", 
                    "AZOPT"
                ], 
                "description": "Inactive ingredients used for masking purposes", 
                "intervention_name": "Travoprost solution vehicle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TRAVATAN Z", 
                "description": "Inactive ingredients used for masking purposes", 
                "intervention_name": "Brinzolamide suspension vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Brinzolamide", 
                "Travoprost", 
                "Cloprostenol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Glaucoma", 
            "Ocular", 
            "Hypertension", 
            "OAG", 
            "POAG", 
            "OHT"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Locations"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A 6-Week Proof-of-Concept Study Evaluating the Safety and IOP-Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension", 
        "overall_contact": {
            "email": "alcon.medinfo@alcon.com", 
            "last_name": "Alcon Call Center", 
            "phone": "1-888-451-3937"
        }, 
        "overall_official": {
            "affiliation": "Alcon Research", 
            "last_name": "James E. Teague, BS", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "IOP (fluid pressure inside the eye) will be assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).", 
            "measure": "Mean IOP at Week 6", 
            "safety_issue": "No", 
            "time_frame": "Week 6, up to 8 pm"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02140060"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}